A clinical trial was conducted to evaluate the combination treatment of an anti-CTLA-4 mAB IBI-310 and an investigational PD-1 inhibitor sintilimab in patients with anti-PD1/PD-L1 resistance R/M NPC (NCT04945421). The gene discussed is CTLA4; the disease is nasopharyngeal carcinoma.